What is Stoke Therapeutics, Inc.'s net investment in lease?

Stoke Therapeutics, Inc. (STOK) reported net investment in lease of $2.49M in Q1 2026.

How has Stoke Therapeutics, Inc.'s net investment in lease changed year-over-year?

Stoke Therapeutics, Inc.'s net investment in lease decreased by 34.9% year-over-year, from $3.83M to $2.49M.

What is the long-term trend for Stoke Therapeutics, Inc.'s net investment in lease?

Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s net investment in lease has grown at a 22.7% compound annual growth rate (CAGR), from $1.12M to $3.1M.

Stoke Therapeutics, Inc. STOK Net Investment in Lease

Net Investment in Lease at other companies

Ionis PharmaceuticalsIONS

——

Jazz PharmaceuticalsJAZZ

——

Xenon PharmaceuticalsXENE

——

Praxis Precision Medicines, Inc.PRAX

——

Nurix Therapeutics, Inc.NRIX

——

Nuvation BioNUVB

——

Other financials

Income statement

See full

Revenue$6.2M-96.1%

Operating income-$53.4M-148%

Net income-$50.0M-144%

EPS (diluted)-$0.79-142%

Balance sheet

See full

Cash & equivalents$155.7M-43.4%

Total debt$3.4M-42.5%

Total equity$394.9M+12.8%

Total assets$443.3M+8.9%

Cash flow

See full

Operating cash flow-$60.6M-146%

CapEx$353.0K+132%

Free cash flow-$60.9M-146%

Valuation

See full

Market cap$1.94B+436%

Enterprise value$1.79B+1,855%

P/S60.4×+58.5×

Profitability

See full

Operating margin-577.5%-597pp

Net margin-529.2%-556pp

FCF margin36.2%+18.4pp

Returns & leverage

See full

Return on equity-45.6%-66.1pp

Debt / equity0×0.0×

Current ratio9×+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stoke Therapeutics, Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Stoke Therapeutics, Inc.'s net investment in lease?: Stoke Therapeutics, Inc. (STOK) reported net investment in lease of $2.49M in Q1 2026.
How has Stoke Therapeutics, Inc.'s net investment in lease changed year-over-year?: Stoke Therapeutics, Inc.'s net investment in lease decreased by 34.9% year-over-year, from $3.83M to $2.49M.
What is the long-term trend for Stoke Therapeutics, Inc.'s net investment in lease?: Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s net investment in lease has grown at a 22.7% compound annual growth rate (CAGR), from $1.12M to $3.1M.